Business Context and Reporting Period
Company: Prana Biotechnology Limited (ASX:PBT)
Filing Type: Form 6-K (Appendix 4D Interim Financial Report)
Reporting Period: Half-year ended 31 December 2015
Business Overview: Prana is a development-stage medical biotechnology company focused on research into Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company has no commercial product revenue; income is derived from interest and government R&D tax incentives.
Key Financial Metrics
| Metric | Half-Year 2015 | Half-Year 2014 |
|---|---|---|
| Revenue (Interest income) | A$77,328 | A$92,581 |
| Other Income (R&D Tax Incentive) | A$2,779,394 | A$3,331,429 |
| Net Loss (After tax) | (A$2,854,825) | (A$1,252,695) |
| Loss Per Share (Basic & Diluted) | (0.53) cents | (0.26) cents |
| Cash and Cash Equivalents | A$29,059,146 | A$34,909,574 (as at 30 June 2015) |
| Trade Receivables (R&D Tax Incentive) | A$9,248,918 | A$6,521,154 (as at 30 June 2015) |
| Net Tangible Assets per Share | 6.79 cents | 7.33 cents (as at 30 June 2015) |
| Operating Cash Flow | (A$7,378,540) | (A$8,411,407) |
Material Changes vs. Prior Period
- Increased Net Loss: The net loss increased by 127.89% to A$2.85 million. This was primarily driven by a decrease in foreign exchange gains (from A$3.25 million to A$1.32 million) and a reduction in R&D tax incentive income.
- Revenue Decline: Revenue decreased by 16.48% to A$77,328 due to lower interest earned on reduced cash balances held in interest-bearing accounts.
- Cash Position: Cash and cash equivalents decreased by approximately A$5.85 million from the previous year-end (30 June 2015) to A$29.1 million, reflecting ongoing operational burn.
- Receivables Increase: Trade receivables increased significantly to A$9.25 million, largely due to accrued R&D tax incentive claims from the Australian Tax Office (A$6.46m for 2015 and A$2.78m for 2016).
Outlook, Risks, and Management Commentary
Operational Updates
- PBT2 (Huntington's Disease): The FDA maintains a Partial Clinical Hold (PCH) based on non-clinical neurotoxicology findings. Management is focused on submitting a comprehensive data package to lift the hold and plans to submit regulatory packages to the EMA and national authorities.
- PBT434 (Movement Disorders): Pre-clinical data supports neuroprotection in models of Parkinson's and atypical Parkinsonian conditions. Preparation for regulatory submission to enable Phase I trials is underway.
- Pipeline: New Metal-Protein Attenuating Compounds (MPAC) candidates have emerged and are undergoing efficacy profiling in animal models.
Liquidity and Going Concern
Directors believe the company is a going concern. Cash on hand (A$29.1m) plus projected R&D tax incentive inflows (A$9.24m) are expected to meet forecast outflows for at least 12 months. The company has a shelf registration for up to US$50 million in securities and 20.01 million unexercised options.
Regulatory Risks
- NASDAQ Compliance: On 6 November 2015, the company was notified of non-compliance with the NASDAQ minimum bid price requirement of US$1.00. The company has 180 days (until 2 May 2016) to regain compliance, with a potential 180-day extension available.
Investor Verification Checklist
- NASDAQ Status: Verify if the company has regained compliance with the US$1.00 minimum bid price requirement by the 2 May 2016 deadline.
- FDA PCH Resolution: Monitor the status of the Partial Clinical Hold on PBT2 and the timeline for lifting the hold.
- R&D Tax Incentive Timing: Confirm the actual receipt dates of the A$9.24 million in receivables from the Australian Tax Office to ensure cash flow projections hold.
- Cash Burn Rate: Assess if the current cash balance of A$29.1 million is sufficient to fund operations through the next 12 months without additional capital raises, given the high operating loss.